AbbVie's Mavyret Receives European Approval, Signaling a Shift in the Hepatitis C Treatment Landscape
Superior Mechanism of Action in Direct-Acting Antiviral Combination Therapy
Mavyret, recently approved by the European Medicines Agency (EMA), is a direct-acting antiviral (DAA) combination therapy consisting of glecaprevir and pibrentasvir. This drug simultaneously targets the NS3/4A protease and NS5A protein of the hepatitis C virus (HCV), effectively blocking the virus's replication process. This complementary mechanism allows for more effective inhibition of viral replication compared to existing single-target therapies. As a result, it is clinically recognized as an innovative treatment that provides patients with a more reliable and faster treatment option.
High Cure Rates Demonstrated Through Phase 3 Clinical Trials
The core basis for this approval lies in the results of the large-scale global Phase 3 clinical trials, ENDURANCE and EXPEDITION. In clinical trials conducted on patients with no prior treatment experience or those who had failed previous treatments, the sustained virologic response at 12 weeks (SVR12) rate, which is the state of undetectable virus 12 weeks after treatment completion, reached an impressive 95% to 99%. In particular, it demonstrated an excellent safety profile even in patients with severe complications such as impaired renal function, further expanding the treatment area. This is an encouraging result that opens up new treatment avenues for hepatitis C patients with complex underlying conditions.
Maximized Patient Convenience Through Shortened Treatment Duration
A key differentiating strength of Mavyret is that it offers a short-course regimen of 8 weeks for most treatment-naive patients, regardless of genotype. Compared to the existing standard treatment regimen of 12 weeks or longer, this significantly reduces the patient's medication burden and dramatically improves medication adherence. The shortened treatment duration not only reduces the patient's medical costs but also provides national health authorities with the benefit of reducing overall healthcare spending. This high cost-effectiveness is expected to be a significant advantage in reimbursement negotiations.
AbbVie Challenges Gilead's Dominance in the Market
This approval has positioned AbbVie as a strong competitor to Gilead Sciences' Epclusa and Harvoni, which have dominated the global hepatitis C market. With annual sales of approximately $1.311 billion in 2024, Mavyret is aggressively expanding its market share with its excellent price competitiveness and short-course treatment advantages. In particular, the competition among pangenotypic DAA products, which cover genotypes 1 through 6, is triggering price reductions, ultimately improving patients' access to treatment.
AbbVie's approval of Mavyret intensifies competition in the global hepatitis C treatment market, which was previously dominated by Gilead Sciences, and is expected to reshape market share. In the global HCV treatment market, which is estimated at approximately $8.16 billion in 2025, the 8-week shortened treatment regimen, validated through Phase 3 clinical trials, maximizes treatment adherence and has established itself as a strong alternative to existing 12-week treatments such as Epclusa. In clinical practice, its convenience of allowing prescriptions without genotype testing and its high cure rate of over 95% (SVR12) facilitate rapid early treatment and patient management. In the long term, it is expected to induce price competition among competing products, alleviate the healthcare financial burden on governments, and significantly improve patients' access to DAA drugs.
Source: EMA (ema)